Hypertensive myocardial fibrosis
A substantial increase in fibrillar collagen has been w x observed in the cardiac ventricles of animals 1 and w x humans 2 with arterial hypertension. Either reactive or reparative hypertensive myocardial fibrosis is the result of both increased collagen types I and III synthesis by fibroblasts and unchanged or decreased extracellular collagen w x degradation 3 . Hemodynamic and non-hemodynamic factors may be involved in the disequilibrium between collagen synthesis and degradation that occurs in hypertension w x 4 . w x w x As shown experimentally 1 and clinically 5,6 , a rise in collagen content increases myocardial stiffness and promotes abnormalities of cardiac function. In addition, the perivascular accumulation of collagen fibers may impair the vasodilator capacity of intramyocardial coronary arteries and contribute to the decrease in coronary reserve, w x which is commonly seen in the hypertensive heart 7 . On the other hand, alterations in the electrical activity of the left ventricle in hypertensive patients have been shown to w x be related to the degree of myocardial fibrosis 6 .
Although microscopic examination of cardiac biopsies is the most reliable method for documenting and measuring myocardial fibrosis, the development of non-invasive methods to indicate the presence of myocardial fibrosis in hypertensive patients would be useful. We have therefore applied a biochemical method based on the measurement of serum peptides derived from the tissue formation and degradation of fibrillar collagens to monitor the turnover of these molecules in rats with spontaneous hypertension Ž . SHR and in patients with essential hypertension.
Biochemical assessment of fibrillar collagen synthesis and degradation

Fibrillar collagen synthesis
Fibrillar collagen is synthesized in the fibroblasts as procollagen containing an amino-terminal and a carboxy-Ž .w x terminal propeptide Fig. 1 8 . After procollagen has been secreted into the extracellular space, the propeptides are removed by specific proteinases, allowing integration of Ž the rigid collagen triple helix into the growing fibril Fig. . w x 1 8 . The 100-kDa procollagen type I carboxy-terminal Ž . propeptide PIP is cleaved from procollagen type I during the synthesis of fibril-forming collagen type I and is Ž . released into the blood-stream Fig. 1 . A stoichiometric ratio of 1:1 exists between the number of collagen type I w x molecules produced and that of PIP released 8 . Circulat-Ž . w x ing PIP is cleared from the blood by the liver Fig. 1 9 . Therefore, the serum concentration of PIP has been proposed as a useful marker of collagen type I synthesis in w x conditions of preserved liver function 10 . This has been confirmed by several clinical observations demonstrating that high serum levels of the propeptide measured by specific radioimmunoassay reflect continuous tissue fibrow x sis 11-13 .
The 42-kDa procollagen type III amino-terminal Ž . propeptide PIIIP is formed during the conversion of procollagen type III to collagen type III and is released Ž . w x into the blood in a stoichiometric fashion Fig. 1 8 . As PIIIP appears to be cleared from the blood via hepatobil-Ž . w x iary elimination Fig. 1 14 , the serum levels of this propeptide have been proposed as a useful marker of collagen type III synthesis in conditions of preserved bile w x excretion 10 . This is sustained by a diversity of clinical Time for primary review 32 days.
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Ž . PII S 0 0 0 8 -6 3 6 3 9 7 0 0 0 7 2 -2 ( )w x 15-17 observations demonstrating that high serum levels of the propeptide reflect ongoing tissue fibrosis.
Fibrillar collagen degradation
The rate-limiting step in the degradation of collagen type I fibrils is catalytic cleavage by interstitial collagenase Ž .w x Fig. 1 18 . This enzyme cleaves all three alpha chains of collagen at a single, specific locus located at a distance of three-fourths from the amino-terminal. The resulting 36-kDa and 12-kDa telopeptides maintain their helical structure and are resistant to further proteolytic degradation. The big telopeptide spontaneously denatures into non-helical gelatin derivatives which, in turn, are completely de-Ž . graded by interstitial gelatinases Fig. 1 .
The small 12-kDa telopeptide resulting from the cleav-Ž . age of collagen type I CITP is found in an immunochemically intact form in blood, where it appears to be derived from tissues with a stoichiometric ratio of 1:1 between the number of collagen type I molecules degraded and that of Ž . w x CITP released Fig. 1 19 . CITP appears to be cleared Ž . w x from the circulation via glomerular filtration Fig. 1 19 . w x In recent studies 19-21 , serum concentrations of the telopeptide were found to be related to the intensity of the degradation of collagen type I fibrils in patients with normal renal function.
Fibrillar collagen synthesis and degradation-derived peptides in arterial hypertension
Animal studies w x
In a recent study 22 , we measured serum PIP and CITP concentrations by specific radioimmunoassays in Ž . normotensive Wistar-Kyoto rats WKY , SHR and SHR Ž . treated with the angiotensin converting enzyme ACE inhibitor, quinapril, for 20 weeks. The Masson trichrome stain was used to evaluate the presence and intensity of interstitial and perivascular fibrosis of the left ventricle, and the deposition of collagen type I was assessed by immunohistochemistry using a specific monoclonal antibody.
In untreated SHR, compared with WKY, we found more extensive interstitial and perivascular fibrosis, increased collagen volume fractions, more marked accumulation of collagen type I, increased serum PIP concentrations Ž .w x and similar serum CITP concentrations Table 1 22 . In quinapril-treated SHR, compared with untreated SHR, we found marked decreases of fibrosis, lower collagen volume fractions, diminished accumulation of collagen type I, decreased PIP concentrations and similar CITP concentra-Ž . w x tions Table 1 22 . A direct correlation was found between the collagen volume fraction and serum PIP in ) P -0.01 compared to WKY and Q-SHR; ) ) P -0.05 compared to WKY and Q-SHR; ) ) ) P -0.001 compared to NI and L-EH. w x untreated SHR 22 . The ratio between PIP and CITP was abnormally increased in untreated SHR and became nor-Ž . malized after treatment in quinapril-treated SHR Table 1 w x 22 . On the other hand, if an equilibrium is to exist between collagen synthesis and degradation, as proposed by Lauw x rent 25 our findings of normal serum concentrations of w x CITP and increased PIPrCITP ratio in SHR 22 suggest that the intensity of the extracellular degradation of collagen type I is not enough to equilibrate the increased extracellular synthesis of collagen type I in this model of genetic hypertension. w x Interestingly, we have calculated that in the SHR 22,26 changes in the cardiac compartment of collagen type I can alter concentrations of PIP and CITP in the circulation and that other extracardiac sources able to elevate the serum concentrations of PIP and CITP can be excluded. We therefore propose that measurement of serum PIP and CITP concentrations may provide indirect diagnostic information on the development of myocardial fibrosis in arterial hypertension.
Human studies
Due to their pharmacological properties neither quinapril w x w x 27 nor lisinopril 28 seems to stimulate either the hepatic or the renal elimination of the above three peptides. Accordingly, the effects of ACE inhibitors on serum PIP and PIIIP concentrations and the ratio PIPrCITP suggest that these agents influence the synthesis andror the degradation of fibrillar collagen. ACE inhibitors can inhibit the synthesis of fibrillar collagen via suppression of the direct stimulatory action exerted on fibroblasts by mechanical w x strain, angiotensin II and aldosterone 29 . On the other hand, it has been shown that active collagenase is selectively inhibited by the plasminogen activator inhibitors Ž .w x PAIs 30 . Since angiotensin II has the capacity to induce w x PAIs 31 , it can be proposed that ACE inhibition may stimulate collagen degradation via the suppression of angiotensin-II-dependent PAI synthesis.
Conclusions and perspectives
The preliminary experimental and clinical data reviewed here suggest that the biochemical monitoring of ( )fibrillar collagen turnover may provide a potential non-invasive method of assessing both the presence and mechanisms of myocardial fibrosis and the ability for cardiac repair of antihypertensive drugs in hypertensive patients.
It is clear that none of the collagen tissue peptides detectable in serum is exclusively heart-specific or unambiguously reflects either fibrogenesis, fibrolysis or fibrosis in hypertensive heart disease. However, if the diagnosis is not established, which is still based primarily on histological assessment, measurement of these peptides or a combination of them should provide information not available by any other known parameter. Nevertheless, we are aware that further clinical and experimental studies are necessary to definitively validate this approach.
While a cardiac-based biopsy protocol is not manageable and beyond that may be subject to sampling error, serum tests can be performed on a frequent basis. This kind of patient control will definitely be necessary, once the availability of potent antifibrotic drugs triggers clinical trials or even leads to novel standard treatment for fibrogenic cardiac diseases, a development which can be anticipated in the immediate future.
